Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Evolus Inc (NQ: EOLS ) 15.95 -0.40 (-2.45%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 872,853 Open 16.43 Bid (Size) 15.80 (5) Ask (Size) 16.73 (10) Prev. Close 16.35 Today's Range 15.88 - 16.50 52wk Range 7.440 - 17.70 Shares Outstanding 54,576,156 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Analyst Scoreboard: 4 Ratings For Evolus September 13, 2024 Via Benzinga Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 September 06, 2024 From Evolus Via Business Wire Performance YTD +59.66% +59.66% 1 Month +0.57% +0.57% 3 Month +45.93% +45.93% 6 Month +13.93% +13.93% 1 Year +75.47% +75.47% More News Read More Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From Evolus Via Business Wire EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024 July 31, 2024 Via InvestorPlace Evolus: Chiseling Away At The Aesthetic Market May 25, 2024 Via Talk Markets Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters Early July 31, 2024 Via Investor's Business Daily Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance July 31, 2024 From Evolus Via Business Wire Evolus to Hold Investor Day on September 12, 2024 July 31, 2024 From Evolus Via Business Wire Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia July 30, 2024 From Evolus, Inc. Via Business Wire Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference July 25, 2024 From Evolus Via Business Wire Evolus to Report Second Quarter Financial Results on July 31, 2024 July 17, 2024 From Evolus Via Business Wire Evolus Announces Appointment of Albert G. White III to Board of Directors July 01, 2024 From Evolus Via Business Wire Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products June 24, 2024 From Evolus Via Business Wire Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain June 12, 2024 From Evolus Via Business Wire Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Evolus Via Business Wire Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting May 20, 2024 From Evolus Via Business Wire Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit May 15, 2024 From Evolus Via Business Wire Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Evolus Via Business Wire Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year May 10, 2024 From Evolus, Inc. Via Business Wire EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Evolus Reports First Quarter 2024 Results and Provides Business Update May 07, 2024 From Evolus Via Business Wire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday May 02, 2024 Via InvestorPlace Evolus to Report First Quarter Financial Results on May 7, 2024 April 23, 2024 From Evolus Via Business Wire Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® April 17, 2024 From Evolus Via Business Wire Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 12, 2024 From Evolus Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
